Morepen Labs Share Price

₹ 90.15

-₹0.62 (-0.68%)
1D
Last updated 20 Nov, 2026, 15:59 IST
NSE: MOREPENLAB
|
Pharmaceuticals

Morepen Labs Share Price Today

As of 21 Nov 2026, Morepen Labs share price is ₹90.15. The stock opened at ₹92.80, compared to its previous close of ₹90.77. During today's trading session, Morepen Labs share price moved in the range of ₹90.01 to ₹93.00, with an average price of ₹91.50 for the day. Looking at its last 52-week, the stock has touched a low of ₹33.05 and a high of ₹150.70. On the performance front, Morepen Labs share price has increased by 112.02% over the last six months and is up 101.09% on a year-on-year basis.


₹90.01
0.68% down today
₹93.00
1D LOW
1D HIGH

Morepen Labs Stock Insights

Latest Earning
Op Profit TrendUp by 56.37% QoQ
Latest Earning
Net Profit TrendUp by 57.75% QoQ
Latest Earning
Revenue TrendUp by 31.27% QoQ
Stock Performance
OutperformingBeat Nifty by 103.97 % in last 6 month
Shareholding Pattern
DIIDII increased stake by 33.32%
Shareholding Pattern
FIIFII increased stake by 135.13%
Morepen Labs stock performance
Open₹92.80
High₹93.00
Low₹90.01
Prev. close₹90.77
Morepen Labs trading activity
Volume18,78,764
Average traded price₹91.38
Last traded time03:59:49 20 Nov
Last traded quantity11

Circuit
L
H
₹85.65
₹94.65
52-week
L
H
₹33.05
₹150.70
Mkt Cap Cr
4,939.80

P/E
26.21

P/B
3.58

ROA
8.17%
ROE
13.65%

ROCE
15.7%

Quick Ratio
1.82

EV/EBITDA
16.67

Based on fundamentals, this stock's

Performance: 1 out of 5, Very Poor
Performance
Very Poor
Morepen Labs. has not beaten FD return of 7%
Valuation: 1 out of 5, Overvalued
Valuation
Overvalued
Morepen Labs. appears overvalued compared to its peers
Earnings: 3 out of 5, Neutral
Earnings
Neutral
Morepen Labs. earnings growth is positive
Peer Comparison
Peer comparison — key ratios
NameMkt Cap CrP/EP/BROAROEROCEQuick RatioEV/EBITDA
Sun Pharmaceutical Industries4,56,593.4441.175.079.61%13.79%18.65%2.3123.87
Divis Laboratories2,96,740.7888.4116.5215.31%18.69%23.83%3.559.23
Torrent Pharmaceuticals1,75,577.8085.159.734.7%11.42%11.37%0.7533.59
Laurus Labs1,24,001.6593.0720.4611.58%22.11%20.91%0.6852.54
Zydus Lifesciences1,19,700.4627.714.297.63%15.1%14.86%0.9116.06
Dr. Reddy's Laboratories1,16,770.9642.092.994.79%7.21%8.58%1.3519.73
Cipla1,14,396.9540.063.236.6%8.18%10.8%2.521.64
Mankind Pharma1,08,630.8648.546.257.82%12.76%14.68%0.7426.33
Aurobindo Pharma1,03,297.5925.912.626.46%10.13%12.76%1.1512.53
Lupin91,412.8717.63.8213.08%21.65%24.54%1.4210.24

Auto-generated based on historical fundamentals; not a recommendation to buy/sell.

Morepen Labs Company Background

ISIN
INE083A01026
Sector Market Cap
₹ 4,939.80 Cr

Morepen Laboratories Limited is a leading pharmaceutical and healthcare company. It manufactures diverse products, including pharmaceuticals, over-the-counter drugs, diagnostic kits and healthcare devices. Morepen has gained recognition for quality and innovation in the healthcare sector.

Morepen began operations in 1985. The founder of the company was Late KB Suri. The company began as a player in the Active Pharma Ingredients (API) market. Later, it advanced the value chain to complicated multi-stage synthesis from basic semi-synthetic goods.

In 1993, Morepen tied-up with Swiss company, Techquim Establishment to produce Loratadine and Cisapride.

The company began working on high-value compounds in 1999 and used robust research and development to create unique technology and forms.

The same year, the company received approval for its facilities based on USFDA (United States Food and Drug Administration) guidelines. Additionally, the company launched its diagnostic division- Medipath, for the first time.

In 2000, the company launched Dr. Morepen’s brand and established a brand-new market category known as Fast Moving Health Goods (FMHG). Furthermore, Morepen partnered with DiaMed AG, another Swiss company, to produce malaria kits and blood grouping products.

In 2001, Morepen acquired the well-acclaimed brand Burnol and the cough and cold brand Lemolate. In 2003, the company joined hands with Analyticon to sell urinalysis reagent strips. Also, it got 180-day marketing rights for the drug in the United States.

Morepen's R&D centre at Baddi, Himachal Pradesh, was recognised by the Government of India in 2019. In the same year, the company launched APIs for many anti-diabetic molecules. During the Covid era, the company launched over 20 products for Covid-19. It collaborated with RDIF to produce Sputnik Vaccines in India.

Morepen Laboratories Limited is a Public limited company incorporated in India. Morepen has been listed on the BSE and NSE since 1992.

Morepen Laboratories Limited’s market capitalisation stood at over ₹2,300 crore as of January 17, 2024. Morepen Lab share price has gained more than 53% in the last three years.

Morepen Laboratories business operations

The company's operations include the development, production, manufacturing, and marketing of a broad spectrum of home health products, branded and generic formulations and active pharmaceutical ingredients (APIs).

Its registered office is located in the Solan District of Himachal Pradesh. The company's manufacturing facilities are located in Himachal Pradesh. And Morepen’s trading, ancillary and associated operations serve both local and international markets.

Morepen has a significant worldwide footprint and exports to more than 82 nations across the globe. It is certified by all-important regulatory bodies, including the USFDA, WHO, and EU health authorities.

Over 100 million customers use Morepen's domestic products, which are sold under the brands Dr. Morepen and Gubb World. These products offer a wide range of OTC, healthcare, and grooming solutions.

The company is also trying to penetrate the anti-cancer segment by exploring development of key drugs, including Ibrutinib, Enzalutamide, Abemaciclib, Palbociclib, Olaparib & Axitinib.

Morepen Labs Financial Highlights

  • Revenue: Morepen Labs reported revenue of ₹1,827.00 crore in FY26 vs ₹1,829.94 crore in FY25. It showed a decrease of 0.16% on a yearly basis.
  • Operating Profit: Morepen Labs reported an operating profit of ₹119.92 crore in FY26 vs ₹155.11 crore in FY25. It showed a decrease of 22.69% on a year-on-year basis.
  • Net Profit: Morepen Labs reported a net profit of ₹95.65 crore in FY26 vs ₹118.02 crore in FY25. It showed a decrease of 18.95% on a yearly basis.

Morepen Labs Quarterly Result Highlights

  • Morepen Labs reported revenue of ₹755.19 crore in Sep 2026, compared with ₹575.31 crore in Jun 2026, representing an increase of 31.27% on a quarter-on-quarter (QoQ) basis.
  • Morepen Labs reported an operating profit of ₹116.54 crore in Sep 2026, compared with ₹74.53 crore in Jun 2026, representing an increase of 56.37% on a quarter-on-quarter (QoQ) basis.
  • Morepen Labs reported a profit of ₹88.89 crore in Sep 2026, compared with ₹56.35 crore in Jun 2026, reflecting an increase of 57.75% on a QoQ basis.
  • The earnings per share (EPS) of Morepen Labs stood at ₹1.73 during Sep 2026.

Data Source: BSE, Company announcements

Securities shown are illustrative, not recommendations. Past performance does not guarantee future results.

Promoters
35.65%
FII
3.43%
Other DII
1.71%
Retail and other
59.20%
Mutual funds
0.00%
Foreign Institutional Investor (FII)
FII shareholding by period
Dec 20251.62%
Mar 20261.59%
Jun 20261.46%
Sep 20263.43%

Morepen Labs Investment Returns

1 day
-0.68%

1 week
-9.52%

1 month
-25.80%

1 year
+101.09%

3 years
+127.36%

5 years
+89.19%

Morepen Labs Share Price History

Morepen Labs share price history by day, showing open and close prices and the percentage change
Day
Open / Close
Change %
20 Nov 26
₹92.80 / ₹90.15
-0.68%
19 Nov 26
₹91.85 / ₹90.77
-1.73%
18 Nov 26
₹89.48 / ₹92.37
+2.20%
17 Nov 26
₹92.49 / ₹90.38
-4.52%
Show more

Morepen Labs Financials

Full statement

Income Statement · Consolidated

Income Statement · Consolidated — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Revenue₹1,805.69₹1,811.58₹1,690.43₹1,417.53
Other Income₹21.31₹18.36₹13.97₹6.13
Total Revenue₹1,827.01₹1,829.94₹1,704.40₹1,423.66
Total Expenses₹1,732.91₹1,674.83₹1,568.99₹1,367.91
Profit Before Tax₹119.92₹155.11₹135.42₹55.76
Tax₹24.27₹37.09₹38.80₹17.08
Profit After Tax₹95.65₹118.02₹96.62₹38.68
EPS - Basic₹1.73₹2.20₹1.88₹0.77
EPS - Diluted₹1.73₹2.20₹1.88₹0.77

Cash Flow · Consolidated

Cash Flow · Consolidated — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Profit before tax₹119.92₹155.11₹135.42₹55.76
Income before WC changes₹153.38₹192.90₹169.61₹83.66
Change in Assets-₹125.19-₹182.08-₹137.60-₹16.00
Change in Liabilities₹29.73₹58.39₹79.48-₹142.28
Change in WC-₹95.46-₹123.69-₹58.12-₹158.28
Cash flow from Operations₹32.64₹32.06₹73.37-₹91.17
Cash flow from Investing-₹123.42-₹321.51-₹83.30-₹46.51
Cash flow from Financing₹97.40₹299.89₹5.20₹143.54
Total Cash Flow₹6.62₹10.44-₹4.72₹5.86
Cash (Start of the year)₹27.38₹16.95₹21.67₹15.80
Cash (End of the year)₹31.19₹27.38₹16.95₹21.67

Balance Sheet · Consolidated

Balance Sheet · Consolidated — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Non-Current Assets₹772.51₹618.73₹404.16₹354.33
Current Assets₹1,163.61₹1,159.37₹889.04₹756.16
Total Assets₹1,936.12₹1,778.10₹1,293.21₹1,110.50
Current Liabilities₹490.30₹500.65₹402.04₹321.16
Net Current Asset₹673.31₹658.72₹487.00₹435.00
Non-Current Liabilities₹198.73₹90.49₹43.93₹36.88
Equity Capital₹1,247.09₹1,186.96₹847.23₹752.45
Total Equity & Liabilities₹1,936.12₹1,778.10₹1,293.21₹1,110.50

Income Statement · Standalone

Income Statement · Standalone — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Revenue₹1,681.20₹1,554.54₹1,537.59₹1,338.88
Other Income₹21.50₹15.72₹12.57₹5.76
Total Revenue₹1,702.69₹1,570.25₹1,550.16₹1,344.64
Total Expenses₹1,614.52₹1,432.67₹1,401.18₹1,281.60
Profit Before Tax₹89.26₹137.59₹148.98₹63.04
Tax₹23.21₹36.01₹38.04₹16.80
Profit After Tax₹66.06₹101.58₹110.94₹46.24
EPS - Basic₹1.21₹1.90₹2.17₹0.92
EPS - Diluted₹1.21₹1.90₹2.17₹0.92

Cash Flow · Standalone

Cash Flow · Standalone — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Profit before tax₹89.26₹137.59₹148.98₹63.04
Income before WC changes₹140.65₹169.51₹171.68₹81.05
Change in Assets-₹97.08-₹176.95-₹118.02-₹48.20
Change in Liabilities₹1.12₹72.58₹61.06-₹118.69
Change in WC-₹95.96-₹104.37-₹56.96-₹166.90
Cash flow from Operations₹20.47₹29.08₹77.36-₹102.12
Cash flow from Investing-₹119.02-₹280.42-₹83.60-₹36.20
Cash flow from Financing₹97.12₹260.47₹0.28₹144.20
Total Cash Flow-₹1.43₹9.12-₹5.96₹5.88
Cash (Start of the year)₹24.43₹15.30₹21.26₹15.38
Cash (End of the year)₹23.00₹24.43₹15.30₹21.26

Balance Sheet · Standalone

Balance Sheet · Standalone — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Non-Current Assets₹988.87₹614.42₹436.40₹374.69
Current Assets₹918.79₹1,106.78₹842.91₹730.85
Total Assets₹1,907.66₹1,721.20₹1,279.31₹1,105.54
Current Liabilities₹346.29₹461.56₹352.64₹290.98
Net Current Asset₹572.50₹645.23₹490.27₹439.87
Non-Current Liabilities₹318.61₹78.15₹37.65₹34.45
Equity Capital₹1,242.76₹1,181.50₹889.02₹780.11
Total Equity & Liabilities₹1,907.66₹1,721.20₹1,279.31₹1,105.54
* All values are in INR Crore
Morepen Labs market depth
Bid quantityBid priceAsk priceAsk quantity
0090.1552
0000
0000
0000
0000
Total bid quantity0
Total ask quantity52
Morepen Labs technical summary
Bearish indicators2
Neutral indicators4
Bullish indicators2
OverallNeutral
by SEBI experts

Expert Pick

EXPPICK
Stop-loss
Stop-loss is locked. Sign in to view.
Entry price
Entry price is locked. Sign in to view.
Target
Target is locked. Sign in to view.
Indicator
Value
Verdict

RSI (14)
35.42
Neutral

ATR (14)
5.85
Neutral

STOCH(9,6)
16.58
Bullish

STOCH RSI (14)
46.6
Neutral

ADX(9)
36.37
Bearish

UO(9)
38
Neutral

ROC(12)
-11.03
Bearish

WillR(14)
-87.4
Bullish
Period
Simple value
Exponential vaue

5D
91.67
91.95

10D
94.32
94.86

20D
103.02
101.02

50D
115.37
105.6

100D
96.13
96.22
Volume trend — traded volume by day
20 Nov18L
19 Nov15L
18 Nov21L
17 Nov40L
16 Nov41L
Average27L

Technical indicators used here are for indicative purposes only. Kindly do not treat it as an investment or trading advice

Compare against other stocks

Morepen Labs
Pharmaceuticals
Add Stock
Add Another

Morepen Labs Returns Calculator

Ex-date: 18 Sep 2026

Morepen Labs Share Price FAQs












Please be aware that Morepen Labs stock prices are subject to continuous fluctuations due to various factors.